A randomized comparison of CPX-351 and FLAG-Ida in high-risk myelodysplastic syndrome: A subgroup analysis of UK NCRI AML19

Priyanka Mehta, Tomas Skacel, Stefan Faderl, Roderick Murphy, Saemi Park, Abin Thomas, Sean Johnson, Alex Legg

doi:10.1016/j.lrr.2026.100609

CrossrefKarta ta’ informazzjoni

A randomized comparison of CPX-351 and FLAG-Ida in high-risk myelodysplastic syndrome: A subgroup analysis of UK NCRI AML19

Priyanka Mehta, Tomas Skacel, Stefan Faderl, Roderick Murphy, Saemi Park, Abin Thomas, Sean Johnson, Alex Legg

Leukemia Research Reports · 2026 · 26 · 100609

DOI: 10.1016/j.lrr.2026.100609 ↗

Astratt Dettalji biblijografiċi

Astratt

Ebda abstract disponibbli.

Dettalji biblijografiċi

Awturi/Awturiċi: Priyanka Mehta, Tomas Skacel, Stefan Faderl, Roderick Murphy, Saemi Park, Abin Thomas, Sean Johnson, Alex Legg
Ġurnal: Leukemia Research Reports
Sena tal-pubblikazzjoni: 2026
Volum / Ħarġa: 26
Paġni: 100609
Pubblikatur: Elsevier BV
DOI: 10.1016/j.lrr.2026.100609
ISSN: 2213-0489
Sors: Crossref

Għarfien li jaqbel max-xogħol tiegħek.

Minn bidu b’xejn u riċerka personali tal-letteratura sal-Research Suite sħiħa.

Ara t-tariffi →

Il-full texts kollha tal-pubblikaturi huma inklużi?

Le. Ir-referenzi biblijografiċi, l-astratti u t-testi sħaħ huma kontenuti differenti. Jekk test sħiħ huwiex disponibbli jiddependi mis-sors, Open Access u l-liċenzji eżistenti tiegħek. Pjan ta’ EUVIMED ma jissostitwix drittijiet addizzjonali tal-pubblikaturi.